Explore Our Publications
Entrada’s commitment to publications & transparency
Entrada is committed to publishing the results of our sponsored research in a transparent, scientifically accurate, and timely manner. Entrada will apply high ethical standards to our publications and presentations and will adhere to recognized industry guidance such as International Committee of Medical Journal Editors (ICMJE) Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals and International Society for Medical Publication Professionals (ISMPP) Good Publication Practice for Communicating Company Sponsored Medical Research.
Upcoming Presentations
-
Results of a Phase 1 Study to Assess the Safety, Pharmacokinetics, and Exon 44 Skipping of ENTR-601-44 in Healthy Human Volunteers
- By: Natarajan Sethuraman, PhD, President of Research and Development, Entrada Therapeutics
- At: 2025 MDA Clinical & Scientific Conference
- On: March 16, 2025
March 16, 2025 -
Exon 45 Skipping, Dystrophin Production, and Functional Improvement with ENTR-601-45 in Preclinical Models of Duchenne Muscular Dystrophy
- By: Mahasweta Girgenrath, PhD, Vice President, Neuromuscular, Entrada Therapeutics
- At: 2025 MDA Clinical & Scientific Conference
- On: March 16, 2025
March 16, 2025 -
Endosomal Escape Vehicle (EEV™)-Conjugated Phosphorodiamidate Morpholino Oligomer (PMO) Therapeutics For The Treatment Of Duchenne Muscular Dystrophy
- By: Katie Miller, PhD, Scientist II, Discovery Chemistry, Entrada Therapeutics
- At: 4th Annual Novel Conjugates Summit
- On: March 26, 2025
March 26, 2025
Past Presentations
-
Exon 45 Skipping and Dystrophin Production with ENTR-601-45 in Preclinical Models of Duchenne Muscular Dystrophy
- By: Amy Hicks, PhD, Associate Director, Neuromuscular, Entrada Therapeutics
- At: 2024 ASGCT Breakthroughs in Muscular Dystrophy
- On: November 19, 2024
DownloadNovember 19, 2024 -
Therapeutic Potential of ENTR-601-44, an Endosomal Escape Vehicle (EEV™)-Oligonucleotide Conjugate for the Treatment of Exon 44 Skip Amenable Duchenne Muscular Dystrophy
- By: Mahasweta Girgenrath, PhD, Vice President, Neuromuscular, Entrada Therapeutics
- At: 2024 ASGCT Breakthroughs in Muscular Dystrophy
- On: November 19, 2024
DownloadNovember 19, 2024 -
The Endosomal Escape Vehicle Platform Safely and Effectively Delivers Oligonucleotide Therapeutics to Skeletal and Cardiac Muscle Tissue for the Potential Treatment of Duchenne Muscular Dystrophy
- By: Leo Ziqing Qian, PhD, Co-Founder & Vice President, Discovery Research, Entrada Therapeutics
- At: TIDES EUROPE
- On: November 14, 2024
DownloadNovember 14, 2024 -
Robust Exon Skipping and Dystrophin Production with Endosomal Escape Vehicle (EEV™)-Oligonucleotide Conjugates in Preclinical Models of Duchenne Muscular Dystrophy
- By: Mahasweta Girgenrath, PhD, Vice President, Neuromuscular, Entrada Therapeutics
- At: EMBO Workshop: Skeletal Muscle Development, Metabolism, and Repair during Homeostasis and Disease
- On: October 16, 2024
DownloadOctober 16, 2024 -
Therapeutic Potential of ENTR-601-44, an Endosomal Escape Vehicle (EEV™)-Oligonucleotide Conjugate for the Treatment of Exon 44 Skip Amenable Duchenne Muscular Dystrophy
- By: Natarajan Sethuraman, PhD, President of Research and Development, Entrada Therapeutics
- At: 29th Annual Congress of the World Muscle Society
- On: October 8, 2024
DownloadOctober 8, 2024 -
Exon 45 Skipping and Dystrophin Production with ENTR-601-45 in Preclinical Models of Duchenne Muscular Dystrophy
- By: Mahasweta Girgenrath, PhD, Vice President, Neuromuscular, Entrada Therapeutics
- At: 29th Annual Congress of the World Muscle Society
- On: October 8, 2024
DownloadOctober 8, 2024